| Literature DB >> 32900383 |
Peng Yin1, Yaoshen Zhang1, Aixing Pan1, Yi Ding1, Liming Zhang1, Chunyang Xu1, Jincai Yang2, Yong Hai3.
Abstract
BACKGROUND: The objective of the study was to evaluate our innovative percutaneous endoscopic transforaminal lumbar interbody fusion (PE-TLIF) for the treatment of lumbar degenerative diseases.Entities:
Keywords: Lumbar degenerative diseases; Minimally invasive surgery; Percutaneous; Spinal endoscope; Transforaminal lumbar interbody fusion
Mesh:
Year: 2020 PMID: 32900383 PMCID: PMC7487608 DOI: 10.1186/s13018-020-01930-0
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Fig. 1The schematic diagram of the primary guide pin (a), retractor (b), and specially designed SAP guide (c)
Fig. 2D Protection cannula. E Protection cannula under the anterior-posterior X-ray film. F Protection cannula under the lateral X-ray film. The hook-shaped device front is attached to the SAP (F1), then the SAP been taken out by the ring saw (F2)
Fig. 3G, the part of the superior articular process were removed. H, traversing nerve root under the endoscope. I, superior endplate. J, fusion cage under the endoscope. K, the front tip of protection cannula
Fig. 4L Pedicle screws were inserted percutaneously. M The appearance of incisions
Fig. 5X-ray images showed the position of internal fixation and cage were favorable
Characteristics of included studies
| Author | Study | Year | Journal | Study design | Number of patients | Age (years) | Male/ female | Indication | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|
| Osman et al. | 1 | 2012 | International Journal of Spine Surgery | RS | 60 | 52.8 (26–85) | 30/30 | DDD (8.3%) LSS (81.7%) SL (10%) | 12 (6-25) |
| Jacquot et al. | 2 | 2013 | International Orthopaedics | RS | 57 | 50.29 (34–71) Male 57.42 (29–90) Female | 17/40 | DDD (100%) PO (33%) | 24 |
| He et al. | 3 | 2015 | International Journal of Surgery | RS | 42 | 64.2 ± 12.8 (37–75) | 23/19 | LSS (81.0%) DSL (14.3%) LDH (4.8%) | 27.6 ± 3.8 (24-36) |
| Morgenstern et al. | 4 | 2015 | International Journal of Spine Surgery | RS | 30 | 62.2 ± 15.9 | 12/18 | DDD (30%) SL (40%) FA (20%) IAD (6.67%) CD (3.33%) | 38 ± 17 (11-67) |
| Wang et al. | 5 | 2016 | Neurosurgical Focus | RS | 10 | 62.2 ± 9.0 (52–78) | 7/3 | DDD (100%) SL (60%) | 12 |
| Lee et al. | 6 | 2017 | BioMed Research International | RS | 18 | 44.1 (26–63) | None | DDD (88.9%) SL (11.1%) | 46 (12-123) |
| Heo et al. | 7 | 2017 | Neurosurgical Focus | RS | 69 | 71.2 ± 7.8 | 24/45 | SL (87.0%) LSS (13%) | 13.5±7.1 |
| Kim et al. | 8 | 2018 | Clinics in Orthopedic Surgery | RS | 14 | 68.7 ± 8.5 (49–85) | None | LSS (57.1%) SL (42.9%) | 2 |
| Wu et al. | 9 | 2018 | BioMed Research International | RS | 7 | 56.0 ± 13.0 (33–72) | 3/3 | SL (100%) | 35.1±3.0 (31.5-38.1) |
RS retrospective case series, DDD degenerative disc disease, LSS lumbar spinal stenosis, SL spondylolisthesis, PO previous operation, DSL degenerative spondylolisthesis, FA failed arthrodesis, IAD instability after decompression, CD chondroma
Interventions and outcomes of included studies
| Study no. | Technique | Fusion level | Operation time (min) | Blood loss (ml) | The length of hospital stay (days) | Clinical effects | Complications | Fusion rate |
|---|---|---|---|---|---|---|---|---|
| 1 | ETD LIF PPSI | L1/2 L2/3 L3/4 L4/5 L5/S1 | 174 (117–251) | 57.6 (30–100) | 2.6 (1–12) | All patients improve on VAS and RMDQ | 8 patients RSE 2 patients RN 2 patients PSC 20% | 59.6% |
| 2 | PETLIF | L3/4 L4/5 L5/S1 | 60 ± 30 | None | 5 (2–21) | 43.9% patients improve on VAS and ODI | 8 patients RPP 13 patients AMC 36% | 77% |
| 3 | FE-MISTLIF | L3/4 L4/5 L5/S1 | 133.9 ± 16.1 one segment 241.3 ± 36.5 Two segments | 221.8 ± 98.5 (100–550) | 9.6 ± 1.3 (7–12) | All patients improve on VAS and ODI success rate 95.2% | 2 patients PNC | 92.9% |
| 4 | PTLIF | L2/3 L3/4 L4/5 L5/S1 | 120 ± 30 (group A or B) 240 ± 120 (group C) | None | 1.1 (0.8–2.8) | All patients improve on VAS and ODI | 3 patients TD 2 patients SIP | None |
| 5 | E-MISTLIF | None | 113.5 ± 6.3 (105–120) | 65 ± 38 (30–190) | 1.4 ± 1.3 | 90% patients improve on ODI, SF-36, EQ-5D | No complications | None |
| 6 | PTLIF | L2/3 L4/5 L5/S1 | 77 (62–100) | None | 1.0 (0.5–2.1) | All patients improve on VAS and ODI | 1 patient PNC 1 patient nonunion 1 patient revision | 88.9% |
| 7 | UBE | L3/4 L4/5 L5/S1 | 165.8 ± 25.5 | 85.5 ± 19.41 | None | All patients improve on VAS and ODI | 2 patients DT 3 patients PEH | None |
| 8 | BE-TLIF | L3/4 L4/5 L5/S1 | 169 ± 10 | 74 ± 9 | None | All patients improve on VAS | 1 patient L5 Paralysis 1 patient DT | None |
| 9 | PELIF | L4/5 | 167.5 ± 30.9 (135–220) | 70.0 ± 24.5 (50–100) | 1.2 ± 0.6 | All patients improve on VAS, SF-36 and ODI | No complications | 100% |
VAS visual analog scale, RMDQ Roland-Morris Disability Questionnaire, ETD endoscopic transforaminal decompression, LIF lumbar interbody fusion, PPSI percutaneous pedicle screw implantation, RSE residual discomfort on extension, RN residual numbness PSC pedicle screw-related complications, PETLIF percutaneous endoscopic transforaminal lumbar interbody fusion, RPP radicular pain with paresthesias, AMC asymptomatic migration of the cages, ODI Oswestry disability index, FE-MISTLIF full-endoscopic minimally invasive transforaminal lumbar interbody fusion, PNC postoperative neurological complications, PTLIF percutaneous transforaminal lumbar interbody fusion, TD transitory dysesthesia, SIP sacroiliac pain, SF-36 36-Item Short Form Health Survey, UBE unilateral biportal endoscopic technique, DT dural tear, PEH postoperative epidural hematoma, BE biportal endoscopic